Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virinder Nohria

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
GanaxoloneVirinder Nohria, Earl Giller
The New England Journal of Medicine|March 12, 2020
Immune ThrombocytopeniaVirinder Nohria, A Christopher Macie
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
RetigabineRoger J Porter, Virinder Nohria, Chris Rundfeldt
Epilepsy Research|March 30, 2010
Clinical development of drugs for epilepsy: a review of approaches in the United States and EuropeRoger J Porter, Michel Baulac, Virinder Nohria
Epilepsy Research|October 8, 2013
Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizuresVictor Biton, Antonio Gil-Nagel, Martin J Brodie, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 24, 2014
A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical developmentRajesh Sachdeo, Arnaud Partiot, Victor Biton, et al.
Epilepsy Research|April 15, 2014
Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerabilityMartin J Brodie, Jacqueline A French, Susan A McDonald, et al.
Oligonucleotides|July 20, 2007
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studiesPeter Hau, Piotr Jachimczak, Reimar Schlingensiepen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
GanaxoloneVirinder Nohria, Earl Giller
The New England Journal of Medicine|March 12, 2020
Immune ThrombocytopeniaVirinder Nohria, A Christopher Macie
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
RetigabineRoger J Porter, Virinder Nohria, Chris Rundfeldt
Epilepsy Research|March 30, 2010
Clinical development of drugs for epilepsy: a review of approaches in the United States and EuropeRoger J Porter, Michel Baulac, Virinder Nohria
Epilepsy Research|October 8, 2013
Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizuresVictor Biton, Antonio Gil-Nagel, Martin J Brodie, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 24, 2014
A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical developmentRajesh Sachdeo, Arnaud Partiot, Victor Biton, et al.
Epilepsy Research|April 15, 2014
Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerabilityMartin J Brodie, Jacqueline A French, Susan A McDonald, et al.
Oligonucleotides|July 20, 2007
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studiesPeter Hau, Piotr Jachimczak, Reimar Schlingensiepen, et al.
Pageof 1